Literature DB >> 10666248

Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.

J ter Meulen1, M Badusche, K Kuhnt, A Doetze, J Satoguina, T Marti, C Loeliger, K Koulemou, L Koivogui, H Schmitz, B Fleischer, A Hoerauf.   

Abstract

T cells must play the major role in controlling acute human Lassa virus infection, because patients recover from acute Lassa fever in the absence of a measurable neutralizing antibody response. T cells alone seem to protect animals from a lethal Lassa virus challenge, because after experimental vaccination no neutralizing antibodies are detectable. In order to study human T-cell reactivity to single Lassa virus proteins, the nucleoprotein (NP) of Lassa virus, strain Josiah, was cloned, expressed in Escherichia coli, and affinity purified. Peripheral blood mononuclear cells (PBMC) obtained from 8 of 13 healthy, Lassa virus antibody-positive individuals living in the Republic of Guinea, western Africa, were found to proliferate in response to the recombinant protein (proliferation index >/=10). PBMC obtained from one individual with a particularly high proliferative response were used to generate 50 NP-specific T-cell clones (TCC). For six of these the epitopes were mapped with overlapping synthetic peptides derived from the sequence of the NP. These CD4(+) TCC displayed high specific proliferation and produced mainly gamma interferon upon stimulation with NP. Because variation of up to 15% in the amino acid sequences of the structural proteins of naturally occurring Lassa virus variants has been observed, the reactivity of the TCC with peptides derived from the homologous epitopes of the Nigeria strain of Lassa virus and of the eastern Africa arenavirus Mopeia was tested. With the Nigeria strain of Lassa virus the levels of homology were 100% for two of these epitopes and 85% for three of them, whereas homology with the respective Mopeia epitopes ranged from 92 to 69%. Reactivity of the TCC with peptides derived from the variable epitopes of the Nigeria strain and of Mopeia was reduced or completely abolished. This report shows for the first time that seropositive individuals from areas of endemicity have very strong memory CD4(+) T-cell responses against the NP of Lassa virus, which are partly strain specific and partly cross-reactive with other Lassa virus strains. Our findings may have important implications for the strategy of designing recombinant vaccines against this mainly T-cell-controlled human arenavirus infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666248      PMCID: PMC111699          DOI: 10.1128/jvi.74.5.2186-2192.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Quantification of epitope-specific MHC class-II-restricted T cells following lymphocytic choriomeningitis virus infection.

Authors:  C Kamperschroer; D G Quinn
Journal:  Cell Immunol       Date:  1999-05-01       Impact factor: 4.868

2.  Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus.

Authors:  M P Kiley; J V Lange; K M Johnson
Journal:  Lancet       Date:  1979-10-06       Impact factor: 79.321

3.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

4.  A case-control study of the clinical diagnosis and course of Lassa fever.

Authors:  J B McCormick; I J King; P A Webb; K M Johnson; R O'Sullivan; E S Smith; S Trippel; T C Tong
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

5.  Standardization of a plaque assay for Lassa virus.

Authors:  O Tomori; K M Johnson; M P Kiley; L H Elliott
Journal:  J Med Virol       Date:  1987-05       Impact factor: 2.327

6.  Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development.

Authors:  P B Jahrling; C J Peters
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

7.  Dissection of human allostimulatory determinants with cloned T cells: stimulation inhibition by monoclonal antibodies TU22, 34, 35, 36, 37, 39, 43, and 58 against distinct human MHC class II molecules.

Authors:  G Pawelec; A Ziegler; P Wernet
Journal:  Hum Immunol       Date:  1985-03       Impact factor: 2.850

8.  Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization.

Authors:  P B Jahrling; J D Frame; J B Rhoderick; M H Monson
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

9.  Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.

Authors:  J C Clegg; G Lloyd
Journal:  Lancet       Date:  1987-07-25       Impact factor: 79.321

10.  A prospective study of the epidemiology and ecology of Lassa fever.

Authors:  J B McCormick; P A Webb; J W Krebs; K M Johnson; E S Smith
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

View more
  58 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

3.  A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.

Authors:  Peter J Bredenbeek; Richard Molenkamp; Willy J M Spaan; Vincent Deubel; Phillippe Marianneau; Maria S Salvato; Dmitry Moshkoff; Juan Zapata; Ilia Tikhonov; Jean Patterson; Ricardo Carrion; Anysha Ticer; Kathleen Brasky; Igor S Lukashevich
Journal:  Virology       Date:  2006-01-18       Impact factor: 3.616

4.  Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus.

Authors:  M Djavani; C Yin; I S Lukashevich; J Rodas; S K Rai; M S Salvato
Journal:  J Hum Virol       Date:  2001 Mar-Apr

5.  A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

Authors:  Anita K McElroy; Rama S Akondy; Jessica R Harmon; Ali H Ellebedy; Deborah Cannon; John D Klena; John Sidney; Alessandro Sette; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

Review 6.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

8.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

Review 10.  Structure-function relationship of the mammarenavirus envelope glycoprotein.

Authors:  Wei Wang; Zheng Zhou; Leike Zhang; Shaobo Wang; Gengfu Xiao
Journal:  Virol Sin       Date:  2016-08-04       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.